Open AccessA Control Model to Evaluate Pharmacotherapy for Allergic Rhinitis in Children
Author(s) -
Gary S. Rachelefsky,
Judith R. Farrar
Publication year - 2013
Publication title -
jama pediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.004
H-Index - 183
eISSN - 2168-6211
pISSN - 2168-6203
DOI - 10.1001/jamapediatrics.2013.623
Subject(s) - medicine , asthma , pharmacotherapy , obstructive sleep apnea , disease , montelukast , pediatrics , medline , randomized controlled trial , nasal administration , intensive care medicine , physical therapy , immunology , political science , law
Although the question of whether early diagnosis and treatment of pediatric allergic rhinitis (AR) improve disease control is important, a more crucial question is whether we can evaluate the effect of treatment on disease control using an impairment-risk model.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom